Proteasome inhibitor Bortezomib/Velcade has emerged as a highly effective anticancer therapy for the treating relapsed and/or refractory multiple myeloma (MM), but long term treatment could be connected with toxicity and development of drug resistance. day time 7; whereas Bortezomib raises T-L activity, which continues to be elevated actually at day time 7. In the framework… Continue reading Proteasome inhibitor Bortezomib/Velcade has emerged as a highly effective anticancer therapy